BBC: VIRTUS BIOTECH CLINICAL TRIALS ETF
What this ETF is trying to do
The VIRTUS BIOTECH CLINICAL TRIALS ETF (ticker: BBC) is an exchange-traded fund designed to invest in the biotechnology sector. Based on its name and holdings, it focuses on companies involved in clinical trials. The fund holds a total of 130 different holdings.
What the numbers show
The current price of BBC is $44.61. When looking at how the fund has performed, it is important to look at both price returns and total returns.
• Price Return: This measures only the change in the share price. The year-to-date (YTD) price return is approximately 15.69%. Over the last year, the one-year price return was approximately 58.50%. Looking further back, the three-year price return was approximately 127.78%.
• Total Return: This includes the share price changes plus any distributions paid out. The YTD total return is approximately 15.69%. The one-year total return was approximately 61.09%, and the three-year total return was approximately 134.64%.
An estimated price from roughly one year ago was $28.15.
Income and distribution explanation
BBC provides some level of cash distributions to investors. The trailing distributions are approximately $0.66 per share, which results in a distribution yield of approximately 1.47%.
It is important to note that the distribution frequency for this ETF is described as "irregular" or "less frequent." In the last 12 months, there was only one payout. Because the frequency is irregular, investors should not expect a steady monthly or quarterly check.
NAV erosion explanation
"NAV erosion" refers to a decline in the Net Asset Value (the actual value of the assets held by the fund). The supplied data is sufficient to evaluate price erosion, but it does not include enough historical NAV-per-share data to confirm or rule out NAV erosion.
However, regarding price-based evidence, the fund has an erosion score of 100, which is labeled as "No price erosion detected." The erosion severity is rated as "good," and there is no severe erosion-risk flag present.
Top Holdings
The following are the top holdings in the portfolio (note that this list is partial):
• ABCELLERA BIOLOGICS INC: 2.01%
• KODIAK SCIENCES INC: 2.01%
• XENCOR INC: 1.46%
• FIRST TRACKS BIOTHERAPEUTICS INC: 1.45%
• AMYLYX PHARMACEUTICALS INC: 1.44%
• MBX BIOSCIENCES INC: 1.19%
• ORIC PHARMACEUTICALS INC: 1.18%
• FDMT: 1.17%
• SELLAS LIFE SCIENCES GROUP INC: 1.14%
• ADLAI NORTYE LTD ADR: 1.12%
Holdings can change over time. This data was updated on October 7, 2026.
Pros
• The fund has shown significant positive price and total returns over the one-year and three-year periods.
• The erosion-risk measurements suggest no significant price deterioration has been detected.
Cons
• The distribution frequency is irregular, meaning income is not consistent.
• The fund is focused on a specific sector (biotech clinical trials), which may behave differently than the broader market.
Beginner takeaway
BBC is a biotech-focused ETF that has experienced strong price growth over the last three years. While it pays distributions, they are infrequent and irregular. When researching, remember that total return includes both price changes and distributions, while the distribution yield only tells you the cash payout relative to the current price.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | ABCELLERA BIOLOGICS INC ORDINARY SHARES | ABCL | 2.01% |
| 2 | KODIAK SCIENCES INC | KOD | 2.01% |
| 3 | XENCOR INC | XNCR | 1.46% |
| 4 | FIRST TRACKS BIOTHERAPEUTICS INC | TRAX | 1.45% |
| 5 | AMYLYX PHARMACEUTICALS INC | AMLX | 1.44% |
| 6 | MBX BIOSCIENCES INC | MBX | 1.19% |
| 7 | ORIC PHARMACEUTICALS INC | ORIC | 1.18% |
| 8 | n/a | FDMT | 1.17% |
| 9 | SELLAS LIFE SCIENCES GROUP INC | SLS | 1.14% |
| 10 | ADLAI NORTYE LTD ADR | ANL | 1.12% |